type in your search and press enter
New Head-to-Head Data Show TALTZ® (ixekizumab) Superiority versus TREMFYA® (guselkumab) in People with Moderate to Severe Plaque Psoriasis
You May Also Like
Inovio Announces Clinical Trial Collaboration to Evaluate a Novel T-cell Immunotherapy in Combination with a PD-L1 Checkpoint Inhibitor
PLYMOUTH MEETING, Pa., June 01, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today ...
Vital Therapies to Present at the 19th International Liver Support Meeting
SAN DIEGO, Sept. 29, 2018 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq: VTL), a ...
